Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …

Angiopoietins 1–4 (Ang1–4) represent an important family of growth factors, whose activities
are mediated through the tyrosine kinase receptors, Tie1 and Tie2. The best characterized …

Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Tumor growth and metastasis rely on tumor vascular network for the adequate supply of
oxygen and nutrients. Tumor angiogenesis relies on a highly complex program of growth …

The endothelial angiopoietin (ANG)–TIE growth factor receptor pathway regulates vascular
permeability and pathological vascular remodelling during inflammation, tumour …

Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers.
Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular …

Simple Summary Tumor growth in solid cancers requires adequate nutrient and oxygen
supply, provided by blood vessels created by angiogenesis. Numerous studies have …

Prostate cancer, a leading cause of cancer death, displays a broad range of clinical
behavior from relatively indolent to aggressive metastatic disease. To explore potential …

Angiopoietins (ANGPTs) are ligands of the endothelial cell receptor TIE2 and have crucial
roles in the tumour angiogenic switch. Increased expression of ANGPT2 relative to ANGPT1 …

The cytokine IL6 has a number of tumor-promoting activities in human and experimental
cancers, but its potential as an angiogenic agent has not been fully investigated. Here, we …